Abstract:Background: Natural killer T-cell lymphoma (NKTCL) is a highly aggressive non-Hodgkin lymphoma with more incidence in Asian and South American populations. Patients suffered from advanced stage disease have limited treatment options and dismal prognosis. Therefore, the development of novel therapeutic targets for the treatment of this debilitating disease is urgently needed. ITK (interleukin-2-inducible kinase, ITK), one of the Tec kinase family, is predominantly expressed in T and natural killer T cells. Though redundant ITK expression was reported in NKTCL, the role of ITK in NKTCL has not been fully investigated. In this study, we elucidate the important role of ITK within the pathogenesis of NK/T cell lymphoma. Methods: Expression level of ITK and p-ITK in NKTCL cell line and patients were performed by immunoblotting and immunohistochemistry, respectively. The lentivirus containing dox-induced ITK targeting shRNA or ITK overexpression plasmid were used to mediate conditional ITK knockdown or stable overexpression of ITK. NKTCL cell line stably transfected dox-induced shRNA or control shRNA plasmids was engrafted in opposite lateral of the same NCG mice to investigate the effect of ITK knockdown in vivo, 4 mg/mL dox in drinking water was administrated to induce ITK knockdown in vivo. The cell viability of tumor cells was analyzed through Cell Titer-Glo® Luminescent Cell Viability Assay. Soft agarose colony forming assay was employed to determine the influence of ITK inhibitor on colony-forming ability of NKTCL cell lines. Results: The expression level of ITK were first analyzed in NKTCL cell lines (KHYG-1, YT, NK-YS and YTS). The KHYG-1 and YT cell showed high level of phosphorylation of ITK activation. Meanwhile, the activation and expression of ITK protein could also be observed in NKTCL patients (n = 17). Next the ITK overexpression plasmid were transfected into NK-YS and YTS cells, which promoted the proliferation of tumor cells. On the other hand, the conditional knockdown of ITK significantly suppressed the growth of KHYG-1 and YT cells. Furthermore, in vivo ablation of ITK in YT mouse model obviously delayed the progression of NKTCL tumors, showing smaller tumor size and lower weight compared with control group, highlighting ITK is a new fragility of NKTCL cells. To further validate this therapeutic effect, NKTCL cells were treated with ITK inhibitors for 24h, 48h and 72h in vitro, The ITK inhibitors repressed the viability of these NKTCL cells in a concentration and time-dependent manner. Furthermore, ITK inhibitors treatment abolished the colony formation of NKTCL cells, which indicated the ITK might represent the potential therapeutic target for NKT cell lymphoma. Taking together, targeting ITK is a promising strategy for treatment NKTCL. Encore Abstract - previously submitted to regional or national meetings (up to <1’000 attendees) Keywords: Aggressive T-cell non-Hodgkin lymphoma, Molecular Targeted Therapies No conflicts of interests pertinent to the abstract.

Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin Lymphoma

Identification of LCK Mutation in a Family with Atypical Epidermodysplasia Verruciformis with T-cell Defects and Virus-Induced Squamous Cell Carcinoma.

Epidermodysplasia Verruciformis and Vδ2 γδ T-cell Expansion in STK4 Deficiency

Interleukin-2 Inducible T-cell Kinase: a Potential Prognostic Biomarker and Tumor Microenvironment Remodeling Indicator for Hepatocellular Carcinoma.

Mycobacterium Intracellulare Infection Associated with TYK2 Deficiency: A Case Report and Review of the Literature

Case Report of Two Independent Moroccan Families with Syndromic Epidermodysplasia Verruciformis and STK4 Deficiency

Inborn Error of STAT2-Dependent IFN-I Immunity in a Patient Presented with Hemophagocytic Lymphohistiocytosis and Multisystem Inflammatory Syndrome in Children

Research-based flow cytometry assays for pathogenic assessment in the human B-cell biology of gene variants revealed in the diagnosis of inborn errors of immunity: a Bruton's tyrosine kinase case-study

Interleukin‐2‐inducible kinase represents a novel therapeutic target for NK/T‐cell lymphoma treatment

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT

Combined immunodeficiency caused by a novel homozygous NFKB1 mutation

Compound heterozygous mutations in the kinase domain of IKKα lead to immunodeficiency and immune dysregulation

Atypical Cutaneous Viral Infections Reveal an Inborn Error of Immunity in 8 Patients

A human immunodeficiency syndrome caused by mutations in CARMIL2

Human interleukin-2 receptor β mutations associated with defects in immunity and peripheral tolerance

Human PLCG2 haploinsufficiency results in a novel natural killer cell immunodeficiency

A role of BPTF in viral oncogenicity delineated through studies of heritable Kaposi sarcoma

Inhibition of kinase IKKβ suppresses cellular abnormalities induced by the human papillomavirus oncoprotein HPV 18E6

Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome

Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases

Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge